CN Patent

CN1098255C — 新的具有速激肽受体拮抗活性的取代的哌嗪衍生物

Assigned to Aventis Pharmaceuticals Inc · Expires 2003-01-08 · 23y expired

What this patent protects

本发明涉及取代的哌嗪衍生物(下文中称为化合物或式(1)的化合物、或其立体异构体、或其药用盐)，及其作为速激肽受体拮抗剂的用途这样的拮抗剂可用来治疗速激肽介导的疾病和症状，本文中公开的有哮喘、咳嗽和支气管炎。

USPTO Abstract

本发明涉及取代的哌嗪衍生物(下文中称为化合物或式(1)的化合物、或其立体异构体、或其药用盐)，及其作为速激肽受体拮抗剂的用途这样的拮抗剂可用来治疗速激肽介导的疾病和症状，本文中公开的有哮喘、咳嗽和支气管炎。

Drugs covered by this patent

Patent Metadata

Patent number
CN1098255C
Jurisdiction
CN
Classification
—
Expires
2003-01-08
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.